A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy
Status:
Not yet recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The ARCH study is an open-label, single-center, Phase 1b study of EDG-5506 to assess the
safety and pharmacokinetics (PK) of EDG-5506 in adults with Becker muscular dystrophy (BMD).
EDG-5506 is an investigational product intended to protect and improve function of dystrophic
muscle fibers.